Tracking and managing the health of HIV-positive women and their infants is crucial in ensuring proper care and treatment. The Maternity Case Record is a comprehensive document that includes information on the mother’s medical history, antenatal care, HIV status, and treatment plan. It allows healthcare providers to monitor the progress of the pregnancy and ensure that the mother receives appropriate care.

The Road to Health Booklet is a similar document for infants, providing a record of their growth, development, immunizations, and any health concerns. It is important for tracking the infant’s health and ensuring they receive necessary medical interventions.

Using these documents in conjunction with a health diary and personal notes can provide a complete picture of the health status of both the mother and infant. Additionally, an electronic health record system can help streamline the tracking and management process by allowing for easy access to patient information and facilitating communication between healthcare providers.

In some cases, a national HIV/AIDS tracking database may also be utilized to monitor the overall health outcomes of HIV-positive women and their infants on a larger scale. By utilizing these recommended documents and systems, healthcare providers can effectively track and manage the health of HIV-positive women and their infants to ensure the best possible outcomes.

HPV genotypes 6 and 11 are considered low-risk types of HPV, meaning they are less likely to cause serious health issues such as cancer. These genotypes are commonly associated with low grade squamous intraepithelial lesions of the cervix (LSIL), which are abnormal changes in the cells of the cervix that are considered to be less severe.

On the other hand, high-risk types of HPV, such as genotypes 16, 18, 31, and 33, are more likely to cause high grade squamous intraepithelial lesions of the cervix (HSIL) and cervical intraepithelial neoplasia (CIN) 2 and 3, which are more severe abnormalities in the cervical cells that can progress to cervical cancer if left untreated.

Therefore, the association of HPV genotypes 6 and 11 with LSIL highlights the importance of HPV genotyping in determining the risk of developing cervical abnormalities and guiding appropriate management and treatment strategies.

Disease state vs Serology
Acute hepatitis: HBsAg, HBeAg, anti-HBc IgM
Chronic hepatitis B (low infectivity): HBsAg (>6/12), anti-HBe, anti-HBc IgG
Chronic hepatitis B (high infectivity): HBsAg (>6/12), HBeAg, anti-HBc IgG
Cleared infection: Anti-HBs, anti-HBe, anti-HBc IgG
Vaccinated: Anti-HBs

Chancroid is a sexually transmitted infection caused by the bacterium Haemophilus ducreyi. It typically presents as painful genital ulcers that can bleed and have a characteristic appearance. In this case, the 4cm bleeding ulcer on the woman’s labia minora is likely due to chancroid.

When a chancroid ulcer is present, it can drain to the lymph nodes in the groin region. The lymph nodes that are most commonly affected in this case are the superficial inguinal lymph nodes. These nodes are located in the groin area and are responsible for draining lymphatic fluid from the lower extremities, external genitalia, and perineum.

Therefore, in this scenario, the bleeding ulcer on the woman’s labia minora would likely drain to the superficial inguinal lymph nodes. It is important to consider the possibility of chancroid in sexually active individuals presenting with genital ulcers, as prompt diagnosis and treatment are essential to prevent complications and further spread of the infection.

Women of childbearing potential with abnormal renal function are at a higher risk for complications during pregnancy, as well as potential adverse effects from certain antiretroviral medications. Tenofovir disoproxil fumarate (TDF) is known to cause renal toxicity in some patients, so it is contraindicated for use in individuals with abnormal renal function.

The recommended regimen for women with abnormal renal function includes zidovudine (AZT), lamivudine (3TC), and dolutegravir (DTG) once daily. AZT and 3TC are both nucleoside reverse transcriptase inhibitors that are safe to use in patients with renal impairment. DTG is an integrase inhibitor that has shown to be effective and well-tolerated in individuals with renal dysfunction.

Therefore, the regimen of AZT, 3TC, and DTG once daily is the most appropriate choice for women of childbearing potential with abnormal renal function, as it provides effective HIV treatment while minimizing the risk of renal toxicity.

Hepatitis B is a viral infection that affects the liver. When someone is infected with hepatitis B, their immune system will typically clear the virus within a few months. However, in some cases, the virus is not completely eliminated from the body and the infection becomes chronic.

The percentage of patients with hepatitis B that develop chronic infection is about 10%. This means that out of every 100 people infected with hepatitis B, approximately 10 will go on to develop a chronic infection. Chronic hepatitis B can lead to serious complications such as cirrhosis (scarring of the liver) and hepatocellular carcinoma (a type of liver cancer).

On the other hand, about 90% of people who are infected with hepatitis B will develop lifelong immunity after clearing the infection. This means that their immune system will be able to recognize and fight off the virus if they are exposed to it again in the future.

The risk of chronic infection and complications like cirrhosis and hepatocellular carcinoma is higher in individuals who are infected with hepatitis B at birth (congenital infection) compared to healthy adults. In healthy adults, the risk of chronic infection and liver complications is lower, at around 5%.

Overall, it is important for individuals who are at risk of hepatitis B infection to get vaccinated and for those who are already infected to receive appropriate medical care and monitoring to prevent the development of chronic infection and its complications.

Anti-HCV IgG antibodies indicate exposure to hepatitis C but this could be acute, chronic or resolved infection. If the antibody test is positive, HCV RNA should be tested for, which if positive indicates that a person has current infection with active hepatitis C.

Neonatal meningitis is a serious infection of the membranes surrounding the brain and spinal cord that occurs in newborn babies. It is most commonly caused by bacteria, with group B Streptococcus being the most common organism in the first month of life. Babies with a meningomyelocele, a type of neural tube defect, have an increased risk of developing neonatal meningitis.

One of the key symptoms of neonatal meningitis is a full anterior fontanelle, but it does not necessarily have to be bulging. Other symptoms include seizures, irritability, poor tone, lethargy, and tremors. While neonatal meningitis can lead to complications such as conductive deafness, it is not always a direct symptom of the infection.

Therefore, the statement that neonatal meningitis has an above average incidence in babies with a meningomyelocele is true. The statement that it is always associated with a bulging anterior fontanelle is false. The statement that it is a risk factor for later conductive deafness is true. The statement that it is most commonly caused by Haemophilus influenzae is false. The statement that it always presents as a febrile illness is false.

Protease Inhibitors: A Breakthrough in HIV and Hepatitis C Treatment

Protease inhibitors are a class of drugs that block the activity of the viral enzyme called protease, which is essential for the maturation of the virus. Initially used for the treatment of HIV, protease inhibitors are now also used for the treatment of hepatitis C infections. Telaprevir is a protease inhibitor specifically designed for hepatitis C virus.

Abacavir and rilpivirine are two other drugs used for HIV treatment. Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI), while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Protease inhibitors are often used as second-line therapy for HIV treatment, with ritonavir commonly used as a booster with other protease inhibitors.

For hepatitis C treatment, protease inhibitors such as telaprevir, boceprevir, simeprevir, and danoprevir are used in combination with interferon and ribavirin. These drugs inhibit NS3/4A protease, which is a promising development in hepatitis C management. They are said to decrease the treatment duration, but their high cost is a major limiting factor for their use.

In conclusion, protease inhibitors have revolutionized the treatment of HIV and hepatitis C infections. While they are not without limitations, they offer hope for patients with these chronic viral diseases.

HIV is a virus that is primarily transmitted through certain bodily fluids, such as blood, semen, vaginal fluids, and breast milk. Unprotected anal or vaginal sexual intercourse with an infected individual is the most common mode of transmission because these bodily fluids can come into contact during sexual activity, allowing the virus to enter the bloodstream of an uninfected person.

Blood transfusion from an infected donor is a rare cause of HIV transmission in countries with strict screening protocols for blood donations. Breastfeeding from an infected mother can also transmit HIV, but the risk is relatively low compared to other modes of transmission. Sharing contaminated needles with an infected individual, such as in the case of intravenous drug use, can also lead to HIV transmission.

It is important for individuals to practice safe sex by using condoms and getting tested regularly for HIV and other sexually transmitted infections to reduce the risk of transmission. Additionally, avoiding sharing needles and ensuring blood products are screened for HIV can help prevent the spread of the virus.

When a pregnant woman is newly diagnosed with HIV, it is important to conduct certain lab tests to assess her overall health and determine the best course of treatment. Creatinine testing is essential to evaluate kidney function, as some HIV medications can affect the kidneys. A CD4 count is also crucial as it indicates the strength of the immune system and helps determine when to start antiretroviral therapy (ART) to prevent mother-to-child transmission of HIV.

Additionally, hepatitis B and C screening is recommended as co-infection with these viruses can worsen the prognosis of HIV. A full hematological profile can provide information on red and white blood cell counts, which may be affected by HIV. Liver function tests are important as HIV can also impact liver health.

Genetic testing for ART resistance may be considered to determine the most effective medications for the pregnant woman. Overall, these lab tests help healthcare providers tailor treatment plans to ensure the best outcomes for both the mother and the baby.

Hepatotoxicity refers to liver damage caused by certain medications, including antiretroviral drugs used to treat HIV. Ritonavir (RTV) is known to have the potential to cause hepatotoxicity, especially when used as a booster for other protease inhibitors. This risk is increased in patients with pre-existing liver disease, as their liver function may already be compromised.

Tenofovir disoproxil fumarate (TDF), nevirapine (NVP), and abacavir (ABC) are other ARV drugs that can also cause hepatotoxicity, but RTV is particularly associated with this side effect. Dolutegravir (DTG) is not typically known to cause hepatotoxicity.

Patients taking RTV, especially those with liver disease, should be closely monitored for signs of liver damage, such as elevated liver enzymes. If hepatotoxicity is suspected, the healthcare provider may need to adjust the treatment regimen or consider alternative medications to minimize the risk of further liver damage.

Infants born to mothers with a high viral load of ≥ 1000 c/ml at delivery are at a higher risk of contracting HIV during childbirth. Therefore, it is recommended to provide these infants with a more aggressive prophylaxis regimen to reduce the risk of HIV transmission.

The recommended prophylaxis for infants born to mothers with a viral load ≥ 1000 c/ml at delivery or with no viral load available is AZT (zidovudine) twice daily for six weeks and NVP (nevirapine) daily for a minimum of 12 weeks. This combination of medications helps to reduce the risk of HIV transmission from mother to child by suppressing the virus in the infant’s system.

It is important to follow the recommended prophylaxis regimen to ensure the best possible outcome for the infant and reduce the risk of HIV transmission. Regular monitoring and follow-up care are also essential to ensure the infant’s health and well-being.

Giardia lamblia is a parasite that can cause a gastrointestinal infection known as giardiasis. One of the symptoms of giardiasis is intestinal malabsorption, which means that the intestines are not able to properly absorb nutrients from food. This can lead to symptoms such as diarrhea, flatulence, abdominal cramps, and greasy stools.

The statement May cause intestinal malabsorption is true because Giardia lamblia can interfere with the normal functioning of the small intestine, leading to malabsorption of nutrients.

The other statements are not true:
– Giardia lamblia is not a common cause of hemolytic uremic syndrome (HUS), which is a condition characterized by the destruction of red blood cells, kidney failure, and low platelet count.
– Giardia lamblia cannot be excluded by stool microscopy, as stool examination for trophozoites and cysts is the preferred method for diagnosing giardiasis.
– Co-trimoxazole (Septrin) is not typically used to treat Giardia lamblia infection. The first-line treatments are metronidazole and tinidazole.
– While Giardia lamblia can cause diarrhea, it does not typically cause bloody diarrhea.

Trichomoniasis is a sexually transmitted disease caused by the protozoan parasite T. vaginalis. While both men and women can be affected, women are more likely to experience symptoms. Diagnosis of trichomoniasis is typically made through wet mount microscopy and direct visualisation, with DNA amplification techniques offering higher sensitivity. Urine testing is not considered the gold standard, and cervical swabs are not sensitive enough. Treatment involves a single dose of metronidazole, and sexual partners should be treated simultaneously. Trichomoniasis may increase susceptibility to HIV infection and transmission. Symptoms in women include a yellow-green vaginal discharge with a strong odour, dysuria, pain on intercourse, and vaginal itching. Men may experience penile irritation, mild discharge, dysuria, or pain after ejaculation.

Neisseria meningitidis is a gram negative bacterium that is commonly referred to as meningococcus. This bacterium is known for causing meningitis and other forms of meningococcal disease, such as meningococcaemia, which is a severe and life-threatening form of sepsis.

The bacterium is classified as a coccus because of its round shape, and more specifically, as a diplococcus because it tends to form pairs. This characteristic can be seen under a microscope when the bacteria are stained and observed.

Among the options provided, the best description for Neisseria meningitidis would be Gram negative cocci, as it accurately reflects the shape and staining characteristics of this bacterium.

HIV transmission through percutaneous exposure, such as a needlestick, occurs when infected blood or bodily fluids enter the bloodstream of an uninfected person. The risk of HIV transmission after a typical percutaneous exposure is estimated to be around 0.3%. This means that out of 100 needlestick injuries, approximately 3 of them may result in HIV infection.

The risk of transmission can vary depending on several factors, such as the viral load of the source individual, the depth of the injury, and the amount of blood involved. For example, if the source individual has a high viral load, the risk of transmission may be higher. Additionally, deeper injuries that involve a larger amount of blood may also increase the risk of transmission.

It is important for healthcare workers and others at risk of percutaneous exposure to take precautions to prevent HIV transmission, such as using appropriate personal protective equipment, following safe needle practices, and seeking immediate medical evaluation and treatment if an exposure occurs. By taking these precautions, the risk of HIV transmission can be minimized.

When managing patients on TLD with an unsuppressed viral load (VL ≥ 50 c/ml), it is important to address the issue promptly to prevent further viral replication and potential development of drug resistance. Switching to a third-line regimen may be necessary if the current regimen is no longer effective, but this should be done after assessing the patient’s resistance profile through a resistance test.

Performing a resistance test is recommended to determine if the unsuppressed viral load is due to drug resistance, which would guide the selection of a new regimen. Increasing the dose of ART medication or temporarily discontinuing ART treatment are not recommended interventions for addressing an unsuppressed viral load.

The immediate intervention recommended for patients on TLD with an unsuppressed viral load is implementing interventions to re-suppress the viral load, which may include Enhanced Adherence Support. This involves working closely with the patient to identify and address barriers to adherence, such as pill burden, side effects, or psychosocial factors, in order to improve medication adherence and achieve viral suppression. Enhanced Adherence Support may include counseling, reminder systems, pill organizers, or other strategies to help the patient adhere to their medication regimen effectively.

The two drugs that act by inhibiting viral reverse transcriptase are the NRTIs (nucleoside reverse transcriptase inhibitors) and NNRTIs (non-nucleoside reverse transcriptase inhibitors). NRTIs work by competing with the natural nucleotides that the virus needs to replicate its genetic material, while NNRTIs bind to a different site on the reverse transcriptase enzyme to prevent it from functioning properly.

In the recommended regimens for post-exposure prophylaxis, the options include using 3 NRTIs, 2 NRTIs plus 1 NNRTI, or using a PI (protease inhibitor) or INI (integrase inhibitor). These combinations of antiviral drugs are effective in preventing the replication of HIV and reducing the risk of acquiring the infection after exposure.

Antiretroviral therapy (ART) is a crucial component of HIV treatment that helps to suppress the virus and prevent disease progression. Therefore, it is generally recommended that ART be initiated as soon as possible after an HIV diagnosis, regardless of the client’s clinical condition or symptoms.

However, there may be certain circumstances where delaying ART is considered. One such circumstance is when concerns about the client’s ability to adhere to the medication regimen outweigh the risk of HIV disease progression. Adherence to ART is essential for its effectiveness, and if a client is unable or unwilling to adhere to the prescribed regimen, it may be more beneficial to delay starting ART until the client is better able to adhere to the treatment plan.

In all other cases, including if the client prefers alternative therapies, if the client’s clinical condition is not severe, if the client is asymptomatic, or if laboratory results are available, ART should not be delayed. The benefits of starting ART early and maintaining adherence to the treatment plan far outweigh any potential risks or concerns in these situations.

Escherichia coli (also known as E. coli) is a gram-negative, facultatively anaerobic, rod-shaped bacterium commonly found in the lower intestine of warm-blooded organisms. Most E. coli strains are harmless, but some serotypes can cause serious food poisoning in their hosts, and are occasionally responsible for product recalls due to food contamination. The harmless strains are part of the normal flora of the gut, and can benefit their hosts by producing vitamin K2, and preventing colonization of the intestine with pathogenic bacteria. Virulent strains can cause gastroenteritis, urinary tract infections, and neonatal meningitis.
The most common causes of neonatal meningitis is bacterial infection of the blood, known as bacteremia (specifically Group B Streptococci (GBS; Streptococcus agalactiae), Escherichia coli, and Listeria monocytogenes). Although there is a low mortality rate in developed countries, there is a 50% prevalence rate of neurodevelopmental disabilities in E. coli and GBS meningitis

The weight-related eligibility criteria for TDF (Tenofovir Disoproxil Fumarate) were decreased from 35 kg to 30 kg according to the 2023 guidelines. This change was made to make TDF more accessible to a wider group of patients initiating antiretroviral therapy (ART). By lowering the weight requirement, more individuals who may benefit from TDF treatment will now be eligible to receive it. This change reflects a commitment to improving access to essential medications for all individuals living with HIV/AIDS, regardless of their weight.

When a mother is diagnosed with drug-resistant TB, it is crucial to refer her to an expert or healthcare provider for guidance on managing the infection. Drug-resistant TB is a serious and complex condition that requires specialized treatment and care. By referring the mother to an expert, she can receive the most up-to-date information on treatment options, potential side effects, and monitoring of the infection. This will ensure that she receives the best possible care and has the highest chance of successful treatment outcomes.

The other options listed do not address the specific needs of a mother diagnosed with drug-resistant TB. Initiating ART immediately may be important for managing HIV co-infection, but it does not address the specific challenges of drug-resistant TB. Obtaining a second opinion on the diagnosis may be helpful in some cases, but it does not provide the specialized care needed for drug-resistant TB. Discussing the possibility of discontinuing TB treatment or assessing eligibility for TB preventive therapy are not appropriate actions for a mother with drug-resistant TB. Therefore, the correct answer is to refer the mother to an expert or healthcare provider for guidance on managing the drug-resistant TB infection.

In this case, the baby’s mother is HIV positive and took antiretrovirals during pregnancy, reducing the risk of vertical transmission of HIV to the baby. However, since the baby was breastfed until six months of age, there is still a possibility of HIV exposure. Therefore, it is crucial to perform an HIV PCR test to determine the baby’s HIV status.

If the baby tests positive for HIV, immediate initiation of combination antiretroviral therapy (cART) is necessary to suppress the virus and prevent disease progression. Additionally, Pneumocystis jiroveci pneumonia (PJP) prophylaxis should be started to prevent opportunistic infections.

The other options provided involve CD4 count and viral load thresholds for initiating cART, which are not applicable in infants. In this case, the focus should be on early diagnosis and treatment to ensure the best possible outcomes for the baby.

The prognosis of an HIV-infected individual is primarily determined by their CD4 count and plasma HIV RNA levels. These factors indicate the progression of the disease and the effectiveness of treatment. Geographic location can also play a role in prognosis, as access to healthcare and treatment options may vary. Economic status can impact prognosis indirectly, as individuals with lower economic status may have less access to healthcare and resources. Genetic makeup can also influence how the body responds to the virus and treatment. However, dietary habits are not a significant factor in determining the prognosis of an HIV-infected individual. While a healthy diet can support overall health and immune function, it is not a direct determinant of HIV progression.

The most appropriate next step in this scenario would be to provide symptomatic relief for the child’s chickenpox symptoms. Chickenpox is a viral infection that typically presents with fever and multiple vesicles on the skin. The recommended treatment for chickenpox includes antihistamines to help with itching, calamine lotion to soothe the skin, and acetaminophen to reduce fever.

Oral acyclovir is not typically used for the treatment of chickenpox in otherwise healthy children, as the infection usually resolves on its own without the need for antiviral medication. Oral antibiotics would not be indicated in this case, as chickenpox is caused by a virus, not bacteria. Topical steroids may be used in some cases to help with itching, but they are not typically the first line of treatment for chickenpox.

Overall, the focus of treatment for chickenpox is on providing comfort and relief from symptoms, rather than targeting the virus itself. It is important to monitor the child’s symptoms and seek medical attention if there are any concerning signs or complications.

If a pregnant woman has a viral load of less than 50 copies/mL at 36 weeks, vaginal delivery is recommended. Therefore, in this case, the correct answer is to proceed with vaginal delivery. It is not necessary to prepare for a caesarian section as the pregnancy is considered safe without surgical intervention. Re-testing the HIV viral load is not necessary as the current recommendation is to test at 36 weeks. Starting antiretroviral infusion during vaginal delivery is also not necessary as the woman is already on regular therapy and has an undetectable viral load. Antiretroviral infusion is typically used during a caesarean section when the viral load is greater than 50 copies/mL.

HIV and Pregnancy: Guidelines for Minimizing Vertical Transmission

With the increasing prevalence of HIV infection among heterosexual individuals, there has been a rise in the number of HIV-positive women giving birth in the UK. In fact, in London alone, the incidence may be as high as 0.4% of pregnant women. The primary goal of treating HIV-positive women during pregnancy is to minimize harm to both the mother and fetus, and to reduce the chance of vertical transmission.

To achieve this goal, various factors must be considered. Firstly, all pregnant women should be offered HIV screening, according to NICE guidelines. Additionally, antiretroviral therapy should be offered to all pregnant women, regardless of whether they were taking it previously. This therapy has been shown to significantly reduce vertical transmission rates, which can range from 25-30% to just 2%.

The mode of delivery is also an important consideration. Vaginal delivery is recommended if the viral load is less than 50 copies/ml at 36 weeks. If the viral load is higher, a caesarean section is recommended, and a zidovudine infusion should be started four hours before the procedure. Neonatal antiretroviral therapy is also typically administered to the newborn, with zidovudine being the preferred medication if the maternal viral load is less than 50 copies/ml. If the viral load is higher, triple ART should be used, and therapy should be continued for 4-6 weeks.

Finally, infant feeding is an important consideration. In the UK, all women should be advised not to breastfeed, as this can increase the risk of vertical transmission. By following these guidelines, healthcare providers can help to minimize the risk of vertical transmission and ensure the best possible outcomes for both mother and child.

Hepatitis C is a viral infection that can be transmitted from mother to baby during pregnancy or childbirth. In the case of the 33-year-old pregnant lady who is hepatitis C positive, it is important to provide accurate information and advice to ensure the health of both the mother and the baby.

Breastfeeding does not increase the risk of transmission of hepatitis C from mother to baby. This is an important fact to remember when counseling the mother.

Co-infection with HIV does increase the risk of transmission of hepatitis C from mother to baby. It is important to monitor and manage both infections in this case.

A high viral load at delivery does increase the risk of transmission of hepatitis C from mother to baby. Close monitoring and appropriate management are necessary in this situation.

Mother to baby transmission of hepatitis C is estimated to be around 5-15%. It is important to provide accurate information about the risk of transmission to the mother.

There is no evidence to suggest that elective Caesarean section reduces the risk of transmission of hepatitis C from mother to baby. It is important to focus on monitoring and managing the infection during pregnancy and childbirth.

Based on the presentation, she probably was administered co-amoxiclav.
The liver function tests are highly suggestive of cholestatic jaundice, which is a classic adverse drug reaction related to co-amoxiclav use.

Other options:
– Erythromycin is more commonly associated with gastrointestinal (GI) disturbance.
– Gentamicin is more commonly associated with renal impairment.
– Meropenem does not commonly cause cholestasis but is associated with transaminitis.
– Vancomycin is associated with red man syndrome on fast administration.

HIV: Transmission, Replication, and Types

HIV, or human immunodeficiency virus, is a virus that attacks the immune system and can lead to acquired immunodeficiency syndrome (AIDS). Here are some important facts about HIV transmission, replication, and types:

Transmission: HIV can be transmitted through certain body fluids, including blood, breast milk, and vaginal/seminal fluids. If these fluids come into contact with a mucous membrane or broken skin, HIV can be transmitted. This means that oral sex can also transmit HIV if vaginal/semen fluids come into contact with the oral cavity.

Replication: HIV is an RNA retrovirus that requires reverse transcriptase to replicate. It contains two copies of genomic RNA. When a target cell is infected, the virus is transcribed into a double strand of DNA and integrated into the host cell genome.

Types: HIV-1 is the most common type of HIV in the UK, whereas HIV-2 is common in West Africa. HIV-1 is more virulent and transmissible than HIV-2. Both types can be transmitted by blood and sexual contact (including oral sex).

Depletion of CD4 T cells: HIV principally targets and destroys CD4 T cells (helper T cells). As a result, humoral and cell-mediated responses are no longer properly regulated, and a decline in immune function results.

Overall, understanding how HIV is transmitted, replicates, and the different types can help in prevention and treatment efforts.